Scholars propose changes to patent disclosures under the Biologics Price Competition and Innovation Act. Biologics—drugs made from organic materials, such as vaccines—are thought to be an important factor driving high drug prices. In the United States, biologics make up over half of prescription medicine spending while accounting for only approximately 3 percent of all prescriptions.